Skip to content
HowShorted

Bionano Genomics, Inc. short interest in 2022

In 2022, Bionano Genomics, Inc.'s disclosed short interest ran from 13.00% of shares outstanding on 14 Jan 2022 to 17.44% on 30 Dec 2022, a change of +4.44 percentage points. The year's high was 17.44% on 30 Dec 2022 and its low 13.00% on 14 Jan 2022, averaging 14.43% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.57 days on 30 Sep 2022. Full history: Bionano Genomics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Bionano Genomics, Inc. in 2022

2022 in figures

Start of year
13.00% (14 Jan 2022)
End of year
17.44% (30 Dec 2022)
Change
+4.44 pp
High
17.44% (30 Dec 2022)
Low
13.00% (14 Jan 2022)
Average
14.43%
Highest days to cover
9.57 (30 Sep 2022)
SEC filings marked
9

Every report in 2022

Bionano Genomics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202213.00%4.28results (8-K)
31 Jan 202213.03%3.85
15 Feb 202213.27%4.89
28 Feb 202213.34%5.30
15 Mar 202213.28%5.1410-K filed, results (8-K)
31 Mar 202213.41%4.76
14 Apr 202215.27%6.59
29 Apr 202215.60%7.36
13 May 202213.78%4.9510-Q filed, results (8-K)
31 May 202213.36%6.74
15 Jun 202213.13%7.30
30 Jun 202215.29%6.52
15 Jul 202215.25%9.28
29 Jul 202215.73%7.94
15 Aug 202213.49%2.1410-Q filed, results (8-K)
31 Aug 202213.04%4.89
15 Sep 202214.13%8.47
30 Sep 202214.85%9.57
14 Oct 202216.10%6.36
31 Oct 202215.41%5.68
15 Nov 202214.39%4.6510-Q filed, results (8-K)
30 Nov 202214.21%7.81
15 Dec 202216.42%5.58
30 Dec 202217.44%7.54

See also: Bionano Genomics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.